Showing 1 - 6 results of 6 for search 'Nithi Mahanonda', query time: 0.04s Refine Results
  1. 1
    The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)

    The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Paruspak Payoong, Nithi Mahanonda

    Published 2023
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST)

    Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged... by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Thachanun Porntharukcharoen, Supamas Sirisreetreerux, Thitapha Thongchai, Kamonwan Soonklang, Nithi Mahanonda

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study

    The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study by Nuttakant Nontawong, Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Mana Boonpratoom, Nawin Krailassiri, Chayaporn Boonkhum, Kamonwan Soonklang, Yong Poovorawan, Nithi Mahanonda

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population

    Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population by Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Harnphadungkit Monprach, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  5. 5
    SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand

    SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand by Teerapat Ungtrakul, Gaidganok Sornsamdang, Kamonwan Soonklang, Siriporn Saeloo, Kasiruck Wittayasak, Ornpreya Suptawiwat, Rojjanaporn Pulmanausahakul, Nanthida Phattraprayoon, Chirayu Auewarakul, Nithi Mahanonda

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  6. 6
    Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

    Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines by Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich, Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: